BBIO
Bridgebio Pharma, Inc.
A biopharmaceutical company developing medicines for genetic diseases, BridgeBio's approved products include Attruby for a heart condition called ATTR-CM and Truseltiq for bile-duct cancer. Founded in 2015, its name reflects a mission of 'bridging' genetic research to patients, and it runs a hub-and-spoke model where small teams advance each drug. Its experimental oral therapy for achondroplasia was the first-ever treatment for children with the condition to earn the FDA's Breakthrough Therapy designation.
CUSIP: 10806X102HealthcareUS3 holders
Total Value
$902.10M
Total Shares
12.15M
Net Share Change
-2.33M
Activity
2 buying1 selling
Investor
Value
Shares
Weight
Change
